Our initial focus is on developing novel immuno-oncology (IO) therapeutics targeting butyrophilins/butyrophilin-like proteins [BTN(L)s] to treat a range of solid tumors and hematologic cancers. Initially, our programs were centered around the powerful mechanism of action of γ9δ2 T cells, however, as our understanding of the BTN(L) biology has evolved we have utilized this knowledge to generate intellectual property around targeting other immune cell populations to create a diversified and deep pipeline.
